SURAKSHASuraksha Diagnostic Ltd.

₹286.4-1.80%

Market Cap

₹1,524.40 Cr

Stock P/E

45.80

ROCE

24.92%

ROE

15.93%

Book Value

₹42.28

Financials

YoY Net Sales

EPS Growth

Operating Margin

You might have missed

No Recent News

No recent news available for this stock.

Shareholding

Holdings

Distribution

Promoter

Institution

Others

From Last Concall

POSITIVES

•
For the full year, we delivered quite a strong performance with total income growing by 15% year-on-year. Our EBITDA also registered a healthy growth of 16% compared to the previous year, with margins maintained at a robust level of approximately 34%.
•
Suraksha Diagnostic continues to strengthen its position as the leading integrated diagnostic service provider in Eastern India, with our operations anchored in a unique and scalable business model.

NEGATIVES

•
Q4 FY25 EBITDA was affected by one-off costs and regulatory changes, including a genomic lab setup cost, ECL provisioning under RCM, and GST-related RCM provisions.
•
New centers contributed to some EBITDA losses in the quarter, with around 30 lakhs of EBITDA impact, although mature centers helped absorb the drag.

Peers Summary

Sector Leader

Suraksha Diagnostic Ltd. exhibits moderate growth and profitability metrics but faces challenges with valuation compared to peers. While it shows effective cash flow management, its high PE ratio indicates it may be overvalued relative to peers. Companies like Narayana Hrudayalaya and Aster DM Healthcare show potential for value due to their low PE and high ROE, while others like Fortis Healthcare and Max Healthcare Institute appear financially weak with high debt levels and low margins.

Key Points

• Suraksha Diagnostic has a moderate revenue growth of 4.14% over 3 years but shows no YoY growth.
• ROE and ROCE are decent at 15.93% and 24.92%, respectively, indicating good efficiency.
• The PE ratio of 46.19 suggests it may be overvalued compared to peers with lower ratios and higher returns.
• Aster DM Healthcare is a standout value pick with a low PE of 5.05 and reasonable profitability metrics.

Top Performers

Narayana Hrudayalaya Ltd.

Best ROE at 24.27% and low PE of 84.56, indicating solid profitability and reasonable valuation.

Aster DM Healthcare Ltd.

Lowest PE ratio of 5.05 and strong cash flow metrics, indicating high value relative to profitability.

Apollo Hospitals Enterprise Ltd.

High EPS growth and decent ROE of 20.51%, but with a high PE suggesting it may be overvalued.

Explore

Watchlists

Command Palette